Abstract: A natural immune agonist complex, consisting of an immune agonist and a targeted liposome, where the immune agonist is M(cGAMP)Ln. The targeted liposome is formed by a nanobody targeting a tumor microenvironment, a cell membrane-targeted penetrating peptide, or a blood-brain barrier-targeted penetrating peptide with a liposome through chemical bonding. This application further provides a preparation and application of the natural immune agonist complex.

Abstract: The present invention belongs to the technical field of biomedicine, and discloses a multi-functional anti-tumor compound drug. A composition of the anti-tumor compound drug comprises an agonist of an innate immune pathway (STING) and an inhibitor of phosphodiesterase ENPP1. Both STING and ENPP1 are located on the endoplasmic reticulum membrane. An activator and the agonist of STING are hydrolysis substrates of ENPP1. The compound drug can have two-pronged effects. The compound anti-tumor drug has a better anti-tumor effect than that by using an innate immune agonist alone. Therefore, the innovative compound anti-tumor drug has an efficient clinical application prospect.

Abstract: The present invention belongs to the technical field of biomedicine, and discloses a novel anti-tumor compound. The anti-tumor compound is an immune activator cisplatin complex prepared from an innate immune pathway agonist and cisplatin drug molecules through a reaction. The anti-tumor drug has dual anti-tumor effects, achieves the two-pronged effects of activating innate immune pathways (generating immune T cells to fight tumors) and fighting tumors by a cisplatin chemotherapy drug, and has the significant effects of fighting tumors, increasing effect and decreasing toxicity as compared with the monofunctional cisplatin anticancer chemotherapy drug. Therefore, the novel immune activator cisplatin anti-tumor drug has an efficient clinical application prospect.